news
Switzerland first country to launch Xultophy® (IDegLira)
19 January 2015 | By Novo Nordisk
Novo Nordisk announced Switzerland as the first country to launch Xultophy® (IDegLira) for people with type 2 diabetes...
List view / Grid view
Novo Nordisk
news
NovoEight®, phase 3 data show reduction in annualised bleeding rate over time in people with haemophilia A
9 December 2014 | By Novo Nordisk
Novo Nordisk announced a new analysis of phase 3 data demonstrating people with haemophilia A who had the highest annualised bleeding rate (ABR) during initial treatment with NovoEight® (turoctocog alfa) showed the largest reduction in bleeding over the duration of treatment...
news
DKSH extends partnership with Novo Nordisk in Malaysia
1 October 2014 | By DKSH Business Unit Healthcare
DKSH, the leading Market Expansion Services provider with a focus on Asia, signed an agreement to provide commercial and distribution services to Novo Nordisk, a global healthcare company with 90 years of experience in diabetes care, in Malaysia...
news
Novo Nordisk establishes new obesity research unit in Seattle
26 September 2014 | By Novo Nordisk
Novo Nordisk announced that the company will establish a new obesity research unit in Seattle, Washington, in the US...
news
New IDegLira (insulin degludec/liraglutide; Xultophy®) data show glycaemic improvements with increased predictability in glycaemic control within one day in people with type 2 diabetes
19 September 2014 | By Novo Nordisk
New analyses of Phase 3a IDegLira (insulin degludec /liraglutide; Xultophy®) DUAL™ study data show an early and substantial improvement in glycaemic control, and a beneficial weight profile in type 2 diabetes patients compared to insulin degludec...
news
Data published in The Lancet show that IDegLira (insulin degludec/liraglutide; Xultophy®) improves glycaemic control in type 2 diabetes with no weight gain and a lower rate of hypoglycaemia compared to insulin degludec
3 September 2014 | By Novo Nordisk
The Lancet Diabetes & Endocrinology has published the phase 3a DUAL™ I study investigating IDegLira (insulin degludec/liraglutide; Xultophy®) − once-daily, single injection insulin degludec (Tresiba®▼ ) and liraglutide (Victoza®)...
news
Mexico first country to launch Ryzodeg®
1 September 2014 | By Novo Nordisk
Novo Nordisk announced that in Mexico, as the first country in the world, Ryzodeg® is now launched and made available for people with type 2 diabetes...
news
Novo Nordisk buys production plant in New Hampshire
27 August 2014 | By Novo Nordisk
Novo Nordisk announced the acquisition of a manufacturing facility in West Lebanon, New Hampshire, USA, from Olympus Biotech...
news
Novo Nordisk accepts fine for violating disclosure obligation in Denmark
19 August 2014 | By Novo Nordisk
Novo Nordisk A/S has accepted a DKK 500,000 fine imposed by the Public Prosecutor in a suit filed by the Danish Financial Supervisory Authority and detailed in a press release issued by Novo Nordisk on 10 December 2013...
news
Novo Nordisk increased operating profit in local currencies by 12% in the first six months of 2014
7 August 2014 | By Novo Nordisk
7% sales growth in local currencies driven by Levemir® and Victoza®...
news
Xultophy® (IDegLira) receives positive opinion from the Committee for Medicinal Products for Human Use for use in adults with type 2 diabetes
29 July 2014 | By Novo Nordisk
Novo Nordisk announced that the Committee for Medicinal Products for Human Use under the European Medicines Agency has adopted a positive opinion for Xultophy®...
news
Phase 3a liraglutide 3 mg trial demonstrated significant weight loss and improved cardiovascular risk factors in adults with obesity and type 2 diabetes compared with placebo
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
news
New phase 3 study shows efficacy and safety of Victoza® for the treatment of type 2 diabetes in adults with moderate renal impairment
16 June 2014 | By Novo Nordisk
Data from a new phase 3 study demonstrated that once-daily Victoza® (liraglutide) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment...
news
Analysis: 6,000 new jobs in Novo Nordisk create a further 15,000 jobs in Denmark
11 June 2014 | By Novo Nordisk
Up to 2022, Novo Nordisk expects to hire 6,000 new employees in Denmark, half of whom will work within research and development...
news
Novo Nordisk to present 63 abstracts at 74th Annual American Diabetes Association Scientific Sessions in San Francisco, CA
10 June 2014 | By Novo Nordisk
Novo Nordisk, will unveil 63 abstracts containing safety and efficacy data from our class-leading portfolio of diabetes products at the 74th Annual Scientific Sessions of the American Diabetes Association...
